Eurobench.com

[verwijderd] 14 april 2017 21:47

0

patentscope.wipo.int/search/docservic...

The present invention provides antagonists of IL-17C for use in the treatment and/or prevention of atopic dermatitis and related conditions.

harvester 25 april 2017 19:02

2

Ook Morphosys houdt een conference call over haar 1e kwartaal cijfers.
Voor zover Galapagos aanstaande vrijdag niet iets zegt over voortgang MOR106, dan doet Morphosys dat wellicht:

Planegg/Munich, Germany, April 24, 2017
MorphoSys to Host Q1 2017 Conference Call on May 3, 2017
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) will publish its first three months’ 2017 results on May 3, 2017 at 7:00 am CEST.
At 3:00 pm CEST (2:00 pm BST, 9:00 am EDT), the Management Board of MorphoSys AG will host a public conference call and webcast to present MorphoSys’s first quarter interim statement 2017 and provide further details on the Company’s latest developments.
Dial-in numbers (listen only):
Germany: +49 89 2444 32975
United Kingdom: +44 20 3003 2666
USA: +1 202 204 1514
We request that you please dial in up to 10 minutes before the call to ensure a prompt start and a secure line.
The presentation slides and webcast link will be available at the Company’s website at www.morphosys.com/conference-calls
A slide-synchronized audio replay of the conference will also be available at the corporate website following the live event.

harvester 4 mei 2017 10:55

1

quote:
harvester schreef op 25 april 2017 19:02:
Ook Morphosys houdt een conference call over haar 1e kwartaal cijfers.
Voor zover Galapagos aanstaande vrijdag niet iets zegt over voortgang MOR106, dan doet Morphosys dat wellicht:

Zojuist de conference call beluisterd. Had al eerder het persbericht gelezen.

Als aandeelhouder van Morphosys werd ik daar vrolijk van en het lijkt erop dat ik niet de enige ben nu de koers van Morhosys aan het oplopen is.
Er wordt nog steeds verwacht dat in december markttoelating verkregen wordt voor een product dat door een van haar partners in december vorig jaar een aanvraag voor markttoelating ingediend werd. Dus volgend jaar krijgt Morphosys ook royalties.

Inzake het project met Galapagos (MOR106) werd in de conference call gesproken over het 4e kwartaal voor de resultaten van de huidige fase 1 studie. Die loopt as planned.

Ook Morphosys bulkt van het geld dus dat zal ook geen vertraging opleveren.

Dus ook goed nieuws over de samenwerking tussen Morphosys en Galapagos. Nog even wachten tot het 4e kwartaal voor nader nieuws.

harvester 23 mei 2017 10:17

0

Ondertussen gaat het ook met Morphosys (en haar Groningse dochter) goed:

19/05/2017
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
18/05/2017
MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017
17/05/2017
MorphoSys AG Reports Outcome of Annual General Meeting 2017
03/05/2017
MorphoSys AG Reports Solid First Quarter 2017

harvester 24 mei 2017 11:53

0

quote:
harvester schreef op 23 mei 2017 10:17:
Ondertussen gaat het ook met Morphosys (en haar Groningse dochter) goed:

19/05/2017
MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
18/05/2017
MorphoSys to Present Clinical Data on Proprietary Programs at Upcoming ASCO Annual Meeting 2017
17/05/2017
MorphoSys AG Reports Outcome of Annual General Meeting 2017
03/05/2017
MorphoSys AG Reports Solid First Quarter 2017

De koers van Morphosys loopt nu wel snel op: inmiddels boven de EUR 65 tot nu toe EUR 2,60 erbij vandaag ofwel ruim 4%.

harvester 25 mei 2017 12:05

1

quote:
harvester schreef op 24 mei 2017 11:53:
[...]

De koers van Morphosys loopt nu wel snel op: inmiddels boven de EUR 65 tot nu toe EUR 2,60 erbij vandaag ofwel ruim 4%.

De koers staat nu op EUR 66 en het is duidelijk waarom:
J+J gebruikt priority voucher voor Guselkumab in in moderate to severe plaque psoriasis, maar gaat ook 3 additionele fase 3 studies starten waarvan 1 in Crohs disease. >> mogelijk concurrentie voor Galapagos+ABBVIE (en voor Vertex).

May 24, 2017 / 11:32 am, CEST

Planegg/Munich, Germany, May 24, 2017

MorphoSys Announces That Its Licensee Janssen Reported Updates on the Development of Guselkumab

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Research & Development, LLC (Janssen), has provided an update on the development of guselkumab. Guselkumab is a fully human anti-IL-23 monoclonal antibody developed by Janssen, and was generated by MorphoSys utilizing its proprietary HuCAL antibody library technology.

According to information provided recently, Janssen has applied a priority review voucher to the guselkumab biologics license application (BLA) with the goal of accelerating the approval process in moderate to severe plaque psoriasis. Pending a positive decision by the FDA, Janssen anticipates a potential US approval of guselkumab may be possible in Q3 2017.

In addition, Janssen announced plans for three new phase 3 clinical trials with guselkumab. These include a phase 3 study to evaluate the comparative efficacy of guselkumab versus secukinumab (Cosentyx(R)) for the treatment of moderate to severe plaque-type psoriasis (ECLIPSE study); a planned phase 3 study in psoriatic arthritis; and plans for a phase 3 program Crohn's disease. According to Janssen the ECLIPSE study has been initiatied and the psoriatic arthritis study is planned to begin enrolling in Q3 2017.

"Following on from our licensee Janssen's successful phase 3 studies VOYAGE 1, VOYAGE 2 and NAVIGATE in moderate to severe plaque psoriasis and the regulatory filings for approval submitted in the U.S. and Europe, we were delighted to learn of Janssen's recent update on guselkumab," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "We are also delighted to hear of Janssen's plans for potentially expanding the range of indications of guselkumab."

harvester 14 juli 2017 09:26

0

Morphosys+J+J :FDA Approval for Tremfya(TM) (Guselkumab) for Plaque Psoriasis

2017-07-13T23:10:32 CET
Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

First antibody generated from MorphoSys's HuCAL library technology to receive marketing approval

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Biotech, Inc. (Janssen), has reported that the U.S. Food and Drug Administration (FDA) has approved Tremfya(TM) (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis. Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys will receive a milestone payment from Janssen in connection with the BLA approval. Financial details were not disclosed.

MorphoSys will provide information on on financial guidance at a later date.

End of adhoc announcement

Cees01 14 juli 2017 09:28

0

Planegg/Munich, Germany, July 13, 2017

MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

First antibody generated from MorphoSys's HuCAL library technology to receive marketing approval

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Biotech, Inc. (Janssen), has reported that the U.S. Food and Drug Administration (FDA) has approved Tremfya(TM) (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis. Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys will receive a milestone payment from Janssen in connection with the BLA approval. Financial details were not disclosed.

Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG, said: "It is a very exciting day for all of us at MorphoSys to have the first antibody generated from our proprietary HuCAL antibody technology receive marketing approval. We are grateful to Janssen for their development efforts and look forward to the launch of Tremfya. Plaque psoriasis is a chronic disease affecting millions of people worldwide, and it is fantastic news that this therapy will now be made available to patients living with moderate to severe disease. We are also very pleased that Janssen is pursuing the development of Tremfya in several additional indications."

Dr. Moroney continued: "With more than 100 MorphoSys compounds currently in development, we look forward to advancing novel antibodies in a wide variety of serious diseases where we see a strong need for alternative treatment options."

Further information can be found in the press release issued by Janssen on July 13, 2017.

MorphoSys will provide information on on financial guidance at a later date.

About Psoriasis
Psoriasis is a chronic, autoimmune inflammatory disorder that results in the overproduction of skin cells, characterised by raised, inflamed, scaly, red lesions, or plaques, which can cause itching and physical pain. It is estimated that as many as 125 million people worldwide have psoriasis, including 14 million Europeans, and approximately 20% of people affected have cases that are considered moderate to severe.

About MorphoSys:
MorphoSys is committed to developing exceptional new treatments for patients suffering from serious diseases. A leader in the field of therapeutic antibodies today, MorphoSys is driven by the ambition of creating the most valuable pipeline of biopharmaceuticals in the biotechnology industry. Based on its proprietary technology platforms, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.

harvester 14 juli 2017 09:36

0

Aandeel MorphoSys CHX:MOR, DE0006632003 koers begint aardig op te lopen, na dit goede nieuws.Ik denk dat nog niet iedereen de betekenis hiervan beseft.

J+J kan beginnen met verkoop dus Morphosys gaat royalty inkomsten krijgen.
Dat is ook goed voor investeringen in andere programma's zoals Mor106 met Galapagos.

Handelen
Volgen
Realtime (EUR) Verschil Volume Bied Laat Vandaag 52W
67,710 +5,290 (+8,47%) 09:30:16
7.130
Gem. 23,9K
-70%
67,460 134 67,720 84 67,060
67,980 35,775
66,620

Bioteg71 14 juli 2017 10:56

0

Marketcap is rond de € 2 mrd (incl. € 340 mln cash) en wat een pipeline hebben ze zeg. Mooi bedrijf.

harvester 14 juli 2017 11:25

0

quote:
Bioteg71 schreef op 14 juli 2017 10:56:
Marketcap is rond de € 2 mrd (incl. € 340 mln cash) en wat een pipeline hebben ze zeg. Mooi bedrijf.

Inderdaad en mijn een na grootste investering.
Overigens zijn de relaties tussen Galapagos en Morphosys uitstekend.

Enkele jaren geleden zei de CEO van Morphosys in verband met de samenwerking in het Mor106 programma "our friends at Galapagos".

Over de pijplijn van Morphosys heeft iemand wel eens gezegd dat die breder lijkt dan hij is omdat zij niet met alles actief zijn. Dat kan zo zijn, maar of dat ligt aan kansen of te weinig centen weten wij geen van allen.

Eind vorig jaar hebben ze met gemak extra geld opgehaald. Dat het met Guselkumab de goed kant op ging was toen wel duidelijk, maar dat J+J een priority voucher heeft ingezet en nu ook daadwerkelijk de markt op mag, maakt het financiële plaatje nog wel een stuk steviger.

Ik ben benieuwd naar de aankondiging van het effect van de markttoelating op de inkomsten (wellicht een aardige milestone nu, naast de royalties) en op de plannen met de pipeline (versnelling van actieve programma's en/of activering van slapende programma's).

Morphosys krijgt mogelijk hetzelfde probleem als Galapagos: een partij (J+J) die het bedrijf voor een product over wil nemen waardoor de rest van de pipeline niet meer de aandacht krijgt die het verdient in de ogen van het huidige management team. J+J heeft met de overname van Crucell op dat vlak een onplezierige reputatie opgebouwd.

harvester 3 augustus 2017 09:58

0

MorphoSys Reports Significant Progress in its Therapeutic Programs in Second Quarter of 2017

August 03, 2017 / 7:00 am, CEST

First proprietary blood cancer program MOR208 enters phase 3 clinical trial; first partnered antibody guselkumab receives market approval

Conference call and webcast (in English) at 2:00pm CEST (1:00pm BST/8:00am EDT)

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, today reported results for the second quarter of 2017.

"We have seen significant progress, both with our own and our partners' drug candidates in the second quarter of 2017. Our progress was particularly evidenced by the start of a phase 3 trial with our blood cancer compound MOR208. This is the first pivotal study with a compound from our own development portfolio and a major milestone for MorphoSys," said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG. "More great news for the pipeline came shortly after the quarter ended, when our partner Janssen announced US FDA approval of TremfyaTM (guselkumab) in plaque psoriasis. This is the best possible validation for our antibody technology and a landmark in the history of MorphoSys. We're extremely happy that TremfyaTM, the first approved product based on our technology, is now available to patients in the US, living with moderate to severe plaque psoriasis."

MorphoSys continues to focus on the research and development of drug candidates. In the second quarter of 2017, group revenues amounted to EUR 11.7 million, comparable with the revenue level in Q2 2016 (EUR 12.2 million).....

In the Proprietary Development segment, MorphoSys focuses its activities on research and clinical development of its own drug candidates in cancer and inflammation.

Earnings before interest and taxes (EBIT) in Q2 2017 amounted to EUR -15.4 million (Q2 2016: EUR -9.5 million). As expected, the operational loss reflects increased spending for the clinical development of the Company's proprietary drug candidates. Three phase 2 studies started with the Company's lead program MOR208 in blood cancer indications during 2016, one of which transitioned into a phase 3 clinical trial in Q2 2017.

Financial guidance confirmed

For the financial year 2017, MorphoSys continues to expect Group revenues in the range of EUR 46 to 51 million. This guidance includes a milestone payment for the TremfyaTM approval. Since royalties for TremfyaTM cannot be accurately projected shortly after the approval, the Company will review its guidance as soon as the revenue uptake allows for reliable projections for the financial year 2017.

"Based on our strong cash position, we continue to drive our proprietary portfolio forward. In particular we will focus on the phase 3 development of our blood cancer candidate MOR208. The approval of TremfyaTM marks our transition to a company whose revenues will be increasingly based on recurring income from product sales. This will contribute to the funding of our proprietary development activities," stated Jens Holstein, Chief Financial Officer of MorphoSys AG.

Operational outlook for 2017

In the Proprietary Development segment, MorphoSys expects the following events in 2017:...

- MOR106: Presentation of results from the ongoing phase 1 trial of MOR106, being co-developed with Galapagos in atopic dermatitis.

In its Partnered Discovery segment, the following events were reported after the end of the reporting period or are further expected:

- TremfyaTM (guselkumab): the first partner-developed therapeutic antibody based on MorphoSys's HuCAL technology has received FDA approval and is now available to patients in the US, according to MorphoSys's partner Janssen. Moreover, guselkumab is currently in review for market approval also in Europe.

- For the remainder of the year, results may be disclosed from up to 25 different clinical studies in various phases conducted by partners with antibodies based on MorphoSys technology.

As always, MorphoSys is in discussions with other companies in the pharmaceutical industry about technology and/or product-based collaborations, with the goal of strengthening its participation in drug programs aimed at unmet medical needs.

MorphoSys will hold its conference call and webcast today to present the second quarter 2017 and first half 2017 financial results and the further outlook for 2017.

Dial-in number for the analyst conference call (in English) at 2:00 pm CEST; 1:00 pm BST; 8:00 am EDT (listen-only):
Germany: +49 (0) 89 2444 32975
For UK residents: +44 (0) 20 3003 2666
For US residents: +1 202 204 1514

Please dial in 10 minutes before the beginning of the conference. A live webcast and slides will be made available at www.morphosys.com.

Shortly after the conference call, a slide-synchronized audio replay of the conference and a transcript will be available on www.morphosys.com.

The half year report (January - June 2017) (IFRS) is available online:
www.morphosys.com/FinancialReports

MorphoSys will hold a Capital Markets Day on September 5 and 6, 2017.

About MorphoSys:
MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders.
Based on its proprietary technology platforms, particularly in the field of fully human therapeuc antibodies, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com.

harvester 14 augustus 2017 15:25

0

conference agenda MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) will present at the following conferences:

Commerzbank Sector Conference
Date: August 29, 2017
Venue: Frankfurt, Germany
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

MorphoSys Capital Markets Day
Date: September 5 and 6, 2017
Venue: London, UK and New York, USA
Participants: Management Board of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

Goldman Sachs 7th Annual Biotech Symposium
Date: September 8, 2017
Venue: London, UK
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

Berenberg and Goldman Sachs Sixth German Corporate Conference
Date: September 18, 2017
Venue: Munich, Germany
Participants: Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

Baader Investment Conference
Date: September 20, 2017
Venue: Munich, Germany
Participants: Jens Holstein, Chief Financial Officer of MorphoSys AG
Anke Linnartz, Head of Corporate Communications & IR

A PDF version of all presentations and, where available, a webcast link to the respective event will be available at www.morphosys.com.

Cees01 5 september 2017 11:20

0

Planegg/Munich, Germany, London, UK, September 5, 2017

MorphoSys Presents Vision for Growth at its Capital Markets Day

- Company is exploring fastest path to market for proprietary blood cancer program MOR208

- Working to secure a deal for proprietary blood cancer program MOR202

- Phase 1 data for MOR106 in atopic dermatitis expected very soon

- New early stage programs announced

- Ambition to bring one new compound into the clinic every 18 months

- Financial guidance for FY 2017 re-confirmed

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, is today hosting its Capital Market Day in London. The Management of MorphoSys AG updated analysts and investors on the Company's growth and development strategy and confirmed its financial guidance for 2017.

"We're excited about the progress in our pipeline. The main focus of our attention is our blood cancer program MOR208, for which we have promising clinical data in DLBCL, a particularly aggressive form of lymphoma. We're working hard to identify the fastest possible path to market for this novel drug candidate", said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG in his opening remarks. "Based on the clinical data we've seen in our clinical trial L-MIND, MOR208 may offer an efficacious, safe, convenient, and affordable treatment to bring patients into remission and keep them there."

Beyond MOR208, MorphoSys is working to secure a deal for its second blood cancer program MOR202, now based on a data package from the phase 1b/2 trial. For MOR106, an antibody in joint development with Galapagos for atopic dermatitis, headline data from an ongoing phase 1 clinical trial is expected to be released soon. The Company's rights to MOR209, an immunotherapeutic for the treatment of metastatic castration resistant prostate cancer, which was in joint development with its originator Aptevo Therapeutics, were recently returned to Aptevo following a portfolio review.

Ambition to bring one new compound into clinic every 18 months
Based on its technological leadership MorphoSys aims to bring a new investigational drug into the clinic every 18 months. A constant inflow of new and innovative drug candidates will ensure that the Company's broad portfolio of proprietary clinical assets is sustained in the future. The focus on its own programs clearly demonstrates the company's firm goal to become a fully integrated bio-pharmaceutical company.

Announcement of new, early-stage programs
MorphoSys also highlighted its earlier stage programs, including a new immuno-oncology program aimed at reversing immunosuppression in cancer. The program is based on a proprietary MorphoSys antibody targeting the C5a receptor, which is intended to enhance patients' immune systems in eradicating tumor cells. The antibody will enter preclinical development this year and is expected to enter the clinic in 2019. Further, the Company revealed early progress in two antibody programs against tumor-associated MHC-peptide targets and announced two bi-specific antibody formats based on proprietary CD3 and 4-1BB antibodies.

Financial guidance for FY 2017 re-confirmed

For the financial year 2017, MorphoSys continues to expect Group revenues in the range of EUR 46 to 51 million. Proprietary R&D expenses were confirmed to be in a corridor of EUR 85 to 95 million. The Company confirmed its guidance for earnings before interest and taxes (EBIT) of EUR -75 to -85 million. This guidance does not include any additional revenue from potential future collaborations and/or licensing partnerships nor effects from potential in-licensing or co-development deals for new development candidates.

"With our strong cash position, we continue to drive forward our proprietary portfolio. In particular, we are focused on the pivotal development of our blood cancer candidate MOR208. Our maturing partnered pipeline is expected to generate increasing cashflows from royalties in the years to come. This will contribute to the funding of our proprietary development activities," said Jens Holstein, Chief Financial Officer of MorphoSys AG. "We see blockbuster potential for Janssen's TremfyaTM, not only for the US psoriasis market, but also in other jurisdictions and indications."

The Capital Markets Day is taking place in London on September 5, 2017 and in New York on September 6, 2017. Presentations and other information material given at the Capital Markets Day are available on our website: www.morphosys.com.

harvester 7 september 2017 10:02

0

September 05, 2017 / 10:45 am, CEST

Planegg/Munich, Germany, London, UK, September 5, 2017

MorphoSys Presents Vision for Growth at its Capital Markets Day

- Company is exploring fastest path to market for proprietary blood cancer program MOR208

- Working to secure a deal for proprietary blood cancer program MOR202

- Phase 1 data for MOR106 in atopic dermatitis expected very soon

- New early stage programs announced

- Ambition to bring one new compound into the clinic every 18 months

- Financial guidance for FY 2017 re-confirmed

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY), a leader in the field of therapeutic antibodies, is today hosting its Capital Market Day in London. The Management of MorphoSys AG updated analysts and investors on the Company's growth and development strategy and confirmed its financial guidance for 2017.

"We're excited about the progress in our pipeline. The main focus of our attention is our blood cancer program MOR208, for which we have promising clinical data in DLBCL, a particularly aggressive form of lymphoma. We're working hard to identify the fastest possible path to market for this novel drug candidate", said Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG in his opening remarks. "Based on the clinical data we've seen in our clinical trial L-MIND, MOR208 may offer an efficacious, safe, convenient, and affordable treatment to bring patients into remission and keep them there."

Beyond MOR208, MorphoSys is working to secure a deal for its second blood cancer program MOR202, now based on a data package from the phase 1b/2 trial. For MOR106, an antibody in joint development with Galapagos for atopic dermatitis, headline data from an ongoing phase 1 clinical trial is expected to be released soon. The Company's rights to MOR209, an immunotherapeutic for the treatment of metastatic castration resistant prostate cancer, which was in joint development with its originator Aptevo Therapeutics, were recently returned to Aptevo following a portfolio review.

Ambition to bring one new compound into clinic every 18 months
Based on its technological leadership MorphoSys aims to bring a new investigational drug into the clinic every 18 months. A constant inflow of new and innovative drug candidates will ensure that the Company's broad portfolio of proprietary clinical assets is sustained in the future. The focus on its own programs clearly demonstrates the company's firm goal to become a fully integrated bio-pharmaceutical company.

Announcement of new, early-stage programs
MorphoSys also highlighted its earlier stage programs, including a new immuno-oncology program aimed at reversing immunosuppression in cancer. The program is based on a proprietary MorphoSys antibody targeting the C5a receptor, which is intended to enhance patients' immune systems in eradicating tumor cells. The antibody will enter preclinical development this year and is expected to enter the clinic in 2019. Further, the Company revealed early progress in two antibody programs against tumor-associated MHC-peptide targets and announced two bi-specific antibody formats based on proprietary CD3 and 4-1BB antibodies.

Financial guidance for FY 2017 re-confirmed

For the financial year 2017, MorphoSys continues to expect Group revenues in the range of EUR 46 to 51 million. Proprietary R&D expenses were confirmed to be in a corridor of EUR 85 to 95 million. The Company confirmed its guidance for earnings before interest and taxes (EBIT) of EUR -75 to -85 million. This guidance does not include any additional revenue from potential future collaborations and/or licensing partnerships nor effects from potential in-licensing or co-development deals for new development candidates.

"With our strong cash position, we continue to drive forward our proprietary portfolio. In particular, we are focused on the pivotal development of our blood cancer candidate MOR208. Our maturing partnered pipeline is expected to generate increasing cashflows from royalties in the years to come. This will contribute to the funding of our proprietary development activities," said Jens Holstein, Chief Financial Officer of MorphoSys AG. "We see blockbuster potential for Janssen's TremfyaTM, not only for the US psoriasis market, but also in other jurisdictions and indications."

The Capital Markets Day is taking place in London on September 5, 2017 and in New York on September 6, 2017. Presentations and other information material given at the Capital Markets Day are available on our website: www.morphosys.com.

About MorphoSys:
MorphoSys's mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders. Based on its proprietary technology platforms, particularly in the field of fully human therapeuc antibodies, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development.
In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs' further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group.
Tremfya(TM) is a trademark of Janssen Biotech, Inc.This communication contains certain forward-looking statements concerning the MorphoSys group of companies.

The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:
MorphoSys AG
Anke Linnartz
Head of Corporate Communications & IR

Jochen Orlowski
Associate Director Corporate Communications & IR

Alexandra Goller
Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404
investors@morphosys.com

harvester 7 september 2017 10:11

0

Thursday, September 7, 2017 - 4:30pm - dus nog even wachten tot de volgende Morphosys webcast na die van capital markets day.
Misschien dan voldoende binnen gedruppeld voro een gezamenlijk persbericht inzake MOR106:

Webcast: Wells Fargo Securities 2017 Healthcare Conference

Dr. Simon Moroney presents the Company at the Wells Fargo Securities 2017 Healthcare Conference, Boston, USA, on Thursday, September 7, 2017, 10:35am EDT, (4:35pm CEST, 3:35pm BST).
Go to Webcast link:
cc.talkpoint.com/well001/090617a_as/?...

harvester 7 september 2017 11:01

0

Aandeel MorphoSys CHX:MOR, DE0006632003 koers loopt op van Morphosys :65.58
Kennelijk komen de presentaties van Morphosys niet alleen bij mij goed over.

Handelen
Volgen
Realtime (EUR) Verschil Volume Bied Laat Vandaag 52W
65,580 +1,980 (+3,11%) 10:54:54
23.613
Gem. 38,4K
-38%

harvester 7 september 2017 12:17

1

MORPHOSYS AG 66,880 12:13:00 +3,280 +5,16%

verder opgelopen..

quote:
harvester schreef op 7 september 2017 11:01:
Aandeel MorphoSys CHX:MOR, DE0006632003 koers loopt op van Morphosys :65.58
Kennelijk komen de presentaties van Morphosys niet alleen bij mij goed over.

Handelen
Volgen
Realtime (EUR) Verschil Volume Bied Laat Vandaag 52W
65,580 +1,980 (+3,11%) 10:54:54
23.613
Gem. 38,4K
-38%

harvester 18 september 2017 09:59

0

Media Release
Planegg/Munich, Germany, September 18, 2017
MorphoSys Announces that its Licensee Janssen received CHMP Positive Opinion for Tremfya™ (Guselkumab) Recommending Approval in Europe
Janssen’s TremfyaTM could become the first antibody generated from MorphoSys’s HuCAL technology to receive market approval in Europe following U.S. FDA approval for the treatment of patients with moderate to severe plaque psoriasis in July 2017
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that Janssen-Cilag International NV (Janssen) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of Tremfya™ (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis in Europe.
TremfyaTM is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys’s proprietary HuCAL antibody technology.

SImon Moroney (CEO Morphosys): Assuming approval by the European Commission, we expect this drug to provide a valuable treatment option for patients living with moderate to severe plaque psoriasis in Europe, after Janssen received U.S. FDA approval for TremfyaTM for the same indication earlier this year.”
MorphoSys is eligible to royalties on net sales based on the product sales of Janssen related to TremfyaTM.

harvester 18 september 2017 11:56

0

Aandeel MorphoSys CHX:MOR, DE0006632003 EUR 68,600 +1,760 (+2,63%) 11:45:25 7.559

Aardige stijging nav het bericht van vandaag, maar weinig volume. Misschien wil gewoon niemand meer verkopen.

Vertraagd	17 apr 2024 17:39
Koers	27,380
Verschil	-0,320 (-1,16%)
Hoog	27,680
Laag	27,160
Volume	104.556
Volume gemiddeld	80.458
Volume gisteren	82.849

12 apr	KBC Securities verlaagt koersdoel Gal...
05 apr	Galapagos toont innovatieve aanpak in...
23 feb	AEX op de waakvlam het weekend in, ko...	2
23 feb	Beursblik: gebrek aan opwaarts potent...
23 feb	Gaat AEX op recordjacht of gaat de be...
23 feb	Update : Galapagos voldoet aan verwac...
19 feb	Beursblik: cashburn belangrijk voor G...
15 feb	Galapagos presenteert nieuwe onderzoe...
01 feb	Galapagos rondt Jyseleca-transactie af
04 jan	Galapagos in zee met Thermo Fisher

Galapagos « Terug naar discussie overzicht

MorphoSys

Meedoen aan de discussie?

Direct naar Forum

Detail

Galapagos nieuws